Pethidine

Pethidine (meperidine; ethyl 1-methyl-4-phenylpiperidine-4-carboxylate) is expressly listed as Pethidine in the Ordinance’s First Schedule and is therefore a dangerous drug. The Ordinance prohibits unlicensed import, export, trade, supply, brokerage, manufacture, preparation, possession and use; its dangerous-drug definition extends the scheduled substance to its preparations and salts. Possession or use pursuant to the Ordinance’s authorization framework, including a properly issued medical prescription, is excepted; this is not a general consumer-legality or decriminalization rule. The Ordinance is in force and was last amended on 7 November 2023. The 2025 Dangerous Drugs Regulations add controlled electronic-prescription dispensing requirements for strong opioid dangerous drugs.

Pethidine (meperidine; ethyl 1-methyl-4-phenylpiperidine-4-carboxylate) falls within the expressly scheduled ester class in Schedule I, rather than being controlled through an analogue provision. Article 2(1)(i) defines substances in Schedule I as narcotics (麻薬). Accordingly, it is a controlled narcotic subject to the Act’s licensing and handling restrictions.

Argentina classifies pethidine (petidina; the ethyl ester of 1-methyl-4-phenylpiperidine-4-carboxylic acid) in List I of the national narcotics schedules. List I is controlled rather than the List IV category of drugs whose production, manufacture, import, export, trade, and use are prohibited; activities involving pethidine require the authorization and health-authority controls established by Ley 17.818, and dispensing is subject to the law's prescription regime. The listing also covers its possible salts, including salts of its esters, ethers, and isomers. Pethidine intermediates A, B, and C are listed separately. Decree 122/2026 currently replaces Annex I to Decree 560/2019 for the Penal Code's narcotic-drug list and took effect the day after its official publication.

Pethidine (Brazilian Portuguese: petidina; also meperidine) is expressly named, not inferred from a related phenylpiperidine, as item 79 of Lista A1. Lista A1 is the narcotics list subject to Notificação de Receita A; authorised medical dispensing is therefore prescription-controlled. The A1 addendum also controls salts, ethers, esters and isomers where they can exist, and salts of those forms; this chemically encompasses pethidine salts such as pethidine hydrochloride. There is no pethidine-specific preparation exemption in the A1 addendum. Update 102 (RDC 1.036/2026) is the current version of Anvisa's controlled-substances lists; its changes concern D1 and F1, not A1. Under Lei 11.343/2006, listed drugs are prohibited nationally except where legally or regulatorily authorised, so possession, supply, production, import or other handling outside the controlled authorisation and prescription framework is not permitted.

Synthetic opioid analgesic; pethidine is also called meperidine.

Pethidine is currently listed by exact Chinese and English name as a medicinal narcotic drug. The 2025 catalogue applies from publication and its general note covers possible salts and single-ingredient preparations unless otherwise specified; the listing is marked with an asterisk, denoting a variety produced and used in China. China controls narcotic drugs: absent a regulatory exception, entities and individuals may not research, produce, trade, use, store, or transport them. Lawful medical supply is confined to approved medical institutions and qualified prescribers; the prescription rule specifically limits pethidine hydrochloride to one dose and use within a medical institution.

Pethidine is expressly listed as a List 1 narcotic by its Czech INN and the same ethyl 4-phenyl-1-methylpiperidine-4-carboxylate chemical identity. It is therefore a controlled addictive substance, and a solution or mixture containing it is a controlled preparation. Handling requires Ministry of Health authorization unless the Act provides an exception. A patient may acquire and keep a medicinal preparation for personal use only on a prescription or as supplied by a healthcare provider; List 1 medicinal preparations are prescribed and dispensed on the special highly-addictive-substance electronic prescription (or, exceptionally, a blue-stripe paper prescription).

Pethidine (meperidine; ethyl 1-methyl-4-phenylpiperidine-4-carboxylate) is expressly listed as Pethidin INN on List B, number 380. List B substances may only be used for medical or scientific purposes. Patient receipt and possession are permitted only through a valid prescription or requisition, or as part of treatment by an authorized clinician; dispensing is limited to the authorized channels specified by the regulation. The control also covers salts, simple euphoric derivatives such as esters and ethers, stereoisomers, and preparations, subject to stated exceptions that do not apply to List B pethidine.

Pethidine is expressly listed as petidiini in Annex I, the Finnish implementation of the 1961 Single Convention lists. The listing expressly covers chemically possible isomers, esters and ethers unless placed in another list, their salts where possible, and preparations containing listed substances except specified List III preparations; no List III pethidine preparation exception is listed. Production, manufacture, import, export, transport, transit, distribution, trade, handling, possession and use are prohibited unless the Narcotics Act's medical, scientific, investigative or control exceptions apply. Medical handling is therefore regulated rather than a general consumer permission.

France expressly classifies pethidine as a narcotic (stupéfiant), rather than relying on a phenylpiperidine or metabolite analogue rule. The current consolidated order lists pethidine and three separately named pethidine intermediates in annex I; the annex's general terms also apply to listed substances' salts, isomers, esters and preparations, subject to stated exceptions. A pethidine medicine is therefore supplied only through the special narcotic-prescription regime; the ANSM product information identifies pethidine as a narcotic and states that its prescription is limited to seven days. The classification does not create a general non-medical possession or supply exception.

Petidina is expressly listed by its matching chemical designation, Asam 1-metil-4-fenilpiperidina-4-karboksilat etil ester. Group II narcotics may be used only for health services and/or scientific development, so pethidine is a tightly regulated medical narcotic rather than generally lawful consumer possession. The Group II annex also covers salts of narcotics in that group. The primary instruments specify no separate preparation exemption or threshold applicable to pethidine. Law No. 35 of 2009 and the 2025 narcotics-classification amendment are in force.

Pethidine is expressly listed in Schedule 2 of the Misuse of Drugs Regulations 2017. The same Schedule separately lists 4-phenylpiperidine-4-carboxylic acid ethyl ester and 1-methyl-4-phenylpiperidine-4-carboxylic acid. Schedule 2 also covers stereoisomeric forms, esters or ethers, salts, and preparations/products containing a scheduled substance, except a Schedule 5 preparation; pethidine is not among the Schedule 5 preparation exceptions. Possession is prohibited unless authorised, while a person may possess a Schedule 2 drug for medical, dental, or veterinary administration under a practitioner's directions. Production, supply, import, and export are generally prohibited, subject to licensed and professional/prescription pathways. The 2024 amending instrument identifies the regulations collectively as the Misuse of Drugs Regulations 2017 to 2024 and only changes Schedule 2 paragraph 6 and Schedule 8, leaving pethidine's Schedule 2 paragraph 1 listing intact.

Mexico expressly lists meperidine (pethidine) as an estupefaciente in Article 234. The Law subjects acts involving narcotics to its control regime and permits their prescription only for medical and scientific purposes, using the special prescription mechanism; the prescription is valid for 30 days and may be dispensed once. The listing does not establish separate coverage for norpethidine, anileridine, phenoperidine, or intermediates.

Pethidine itself—not merely a metabolite, isomer, analogue, or specified product—is expressly listed in Opiumwet List I and in Opiumwetbesluit Annex 1(a). Opiumwet article 4(1) prohibits prescribing a List I or II medicine unless designated by general administrative order. Opiumwetbesluit article 2(1) prohibits prescribing opium-law medicines other than those in its annexes, and Annex 1(a) names pethidine; it is therefore prescription-only under the controlled-medicine regime, not categorically prohibited. Opiumwet article 5 provides the professional and lawful-medical-use exceptions to the underlying List I prohibitions, subject to the decree's prescription and dispensing rules.

Pethidine is expressly listed in Schedule 2, the Class B controlled-drugs schedule. The Act restricts possession, supply, manufacture, import and export except as authorised by the Act, regulations, a licence, or a statutory exemption. Prescribing/supply may occur under the controlled-drug framework; pethidine is a Class B opioid, for which the regulations limit a prescription to the quantity reasonably required for one month of treatment and normally limit dispensing to one month's use. The Act's definition of controlled drug includes a scheduled substance, preparation, mixture, or article; pethidine is expressly listed rather than controlled through identity transfer from other phenylpiperidines or metabolites.

Pethidine is a Philippine dangerous drug because RA 9165 § 3(j) includes the 1961 Convention schedules annexed to the Act, and the DDB regulation repeats that definition. Its treaty and Philippine classifications are Schedule I and Philippine Schedule 2, respectively—not 1961 Schedule II or Philippine Schedule 3. A medical practitioner needs a valid PDEA S-2 license to prescribe a dangerous drug or its preparation; the regulation defines a prescription as a written direction for a named patient and an ultimate user as a person who lawfully obtained and possesses a dangerous-drug preparation for personal use. Unauthorised importation, supply, and possession are offences under RA 9165.

Pethydyna is expressly listed as PETHYDYNA in the Polish I-N narcotic-drug schedule. I-N narcotics may be used only for medical, industrial, or research purposes. Unauthorized possession is an offence; preparations containing narcotic drugs are dispensed by pharmacies only on a specially marked prescription or requisition. The schedule’s I-N class provision also covers salts where their existence is possible, including pethidine salts, but not other phenylpiperidines merely by structural similarity.

Portugal expressly lists Petidina in table I-A of Decreto-Lei n.º 15/93. This is the Portuguese designation for pethidine (meperidine; ethyl 1-methyl-4-phenylpiperidine-4-carboxylate), rather than norpethidine, anileridine, phenoperidine, or a pethidine intermediate. Table I-A substances are controlled under that decree; pethidine is available only through the regulated medical-medicinal channel, not for unlicensed possession, supply, import, export, manufacture, or use.

Pethidine is expressly listed as a Class A controlled drug in Part 1 of the Act's First Schedule. The listing independently covers its stereoisomers (other than the stated dextromethorphan/dextrorphan exception), esters or ethers where not placed in Part 2, salts, and preparations or other products containing it. Pethidine is also expressly in the Regulations' Second Schedule. Accordingly, its possession, supply, manufacture and administration are unlawful except under the Act or Regulations: authorised persons may possess, supply or administer it for the stated professional, research or medical purposes, and a person may possess it for medical, dental or veterinary administration in accordance with a practitioner’s or collaborative prescribing practitioner’s directions. Non-exempt prescriptions must meet the Regulations' form requirements and may be supplied only from their stated date through 30 days afterward. The First Schedule's limited exempt preparations do not list pethidine.

Pethidine is expressly listed in South Africa's current consolidated Schedule 6. Schedule 6 sale requires a written prescription from an authorised prescriber (or qualifying verbal instructions in the statutory emergency arrangements), is not repeatable without a new prescription, and is limited to a course of no more than 30 consecutive days. Possession is permitted with an authorised prescription; manufacture, use, or supply for a non-medicinal purpose requires a Director-General permit. The Drugs and Drug Trafficking Act separately lists pethidine in Schedule 2 Part II, so unauthorised possession or dealing is criminal while Medicines Act-compliant medicinal acquisition, possession, and supply are excepted. The Schedule 2 Part II class expressly includes chemically possible isomers, esters, ethers, salts, preparations, mixtures, and homologues unless expressly excluded or separately scheduled; it covers chemically applicable forms of pethidine, not unrelated phenylpiperidines.

Pethidine is expressly named in the current Enforcement Decree's Attached Table 1 of narcotics rather than controlled through a phenylpiperidine class. South Korea does not assign it a numbered schedule in this instrument; its control tier is the statutory narcotic class. The Narcotics Control Act restricts narcotics handling to the Act's authorized framework, while Article 32 permits a medical practitioner to administer or prescribe a narcotic for medical treatment. This permits prescription-only regulated medical access, not general lawful possession. The direct listing controls pethidine itself, not norpethidine, anileridine, phenoperidine, or other related substances. The official listing's applicable general wording also covers the listed substance's salts and preparations.

La petidina, que corresponde a pethidine/meperidine y al éster etílico del ácido 1-metil-4-fenilpiperidina-4-carboxílico, figura expresamente en la Lista I de la Convención Única vigente para España. La Ley 17/1967 la trata por ello como estupefaciente: solo permite usos industriales, terapéuticos, científicos y docentes autorizados; los preparados para medicina humana o veterinaria se dispensan únicamente por farmacias legalmente establecidas mediante prescripción facultativa y receta oficial. El Real Decreto 1675/2012 exige receta oficial de estupefacientes para medicamentos que contengan sustancias de la Lista I, limita cada receta humana a un medicamento y hasta tres meses de tratamiento (máximo cuatro envases), y exige dispensación por farmacia autorizada.

Turkey's Law No. 812 incorporates the 1961 Single Convention on Narcotic Drugs, whose Schedule I expressly lists pethidine and whose article 4 limits covered production, manufacture, export, import, distribution, trade, use, and possession to medical and scientific purposes. The Ministry of Health's red-prescription narcotic-drug list expressly names pethidine hydrochloride and the Aldolan, Aldine, Petholan, Petisel, and Dolantin 100 mg/2 ml ampoule products. Circular No. 2016/1 requires pharmacies to supply controlled medicines only after the responsible pharmacist has seen and taken the required prescription. Circular No. 2017/1 generally requires narcotic medicines to be prescribed electronically on red prescriptions through the Renkli Reçete System and dispensed after the pharmacist retrieves and records the prescription. It permits paper red or green prescriptions when the system is unavailable or a healthcare provider is not yet integrated, provided the prescription contains the required system-unavailable statement and the prescribing physician's wet-signature approval; for medicines brought from abroad for a specific person; for veterinary prescriptions; and for compounded prescriptions containing a controlled substance absent from the system. Pharmacists must manually record these exception prescriptions in the system. Circular No. 2018/1 continues the electronic procedure and limits red-prescription medicine sales notifications to the Renkli Reçete System or reimbursement institutions. Turkish Penal Code article 188(3) provides at least ten years' imprisonment and a judicial fine of 1,000 to 20,000 days for specified unauthorized domestic sale, offering for sale, supply, dispatch, transport, storage, purchase, acceptance, or possession. Under article 188(6), the preceding article 188 provisions apply to covered prescription substances producing a narcotic or stimulant effect, but the penalty imposed may be reduced by up to one half. Article 191(1) provides two to five years' imprisonment for purchase, acceptance, possession, or use for personal use. Licensed or prescribed medical handling therefore remains available through the controlled legal channel.

Pethidine is individually listed as a Narcotic, Schedule I, in the Ministry of Health and Prevention's controlled-medicines list. Federal Decree by Law No. (30) of 2021 prohibits possession, acquisition, import, export, manufacture, and related acts involving substances in Schedule 1 except within its regulated medical/scientific framework. Personal use outside authorised circumstances, including use above the prescribed dose, is punishable; a narcotic prescription may be issued only by a physician licensed in the UAE where medical treatment requires it. The listing covers pethidine itself, not the separately listed pethidine intermediates or other phenylpiperidines.

Synthetic opioid analgesic; lawful clinical supply remains possible under controlled-drug rules.

Under U.S. federal law, meperidine is regulated as a scheduled opiate and is listed in Schedule II. Selling it requires a DEA license, while buying or possessing it requires either a license or a prescription.

Pethidine (French: péthidine; also meperidine) is expressly listed in Annex Ia as ‘1-methyl-4-phenylpiperidine-4-carboxylic acid ethyl ester.’ Annex Ia also covers chemically possible isomers, esters and ethers (unless placed in Annex Ib), and salts including salts of those derivatives. The Decree applies to listed substances and preparations. Import, export, transport, manufacture, production, possession, sale, supply, dispensing and acquisition require an activity authorization, which is personal and limited to scientific or medical purposes; legally obtained medicines may be acquired or possessed, and public dispensing requires a signed, dated medical prescription. Violations are punishable under the 1921 Drugs Law. This is therefore a tightly regulated narcotic, not an unscheduled substance or a general analogue-only finding.

Petidina is explicitly identified as the DCI synonym of meperidina and is subject to Colombia's State monopoly, including products containing it. Resolution 315 of 2020 adopts the controlled-substances list, extends fiscalization to mixtures and products (particularly medicines), and retains regulated medical, scientific, import, manufacture, distribution, and dispensing pathways through registration/authorization. The underlying control regime requires an official prescription form for medicines of special control and State monopoly; it is not an unrestricted substance.

Medicinal use is permitted.